TBPHTHERAVANCE BIOPHARMA INC
CUSIP G8807B106 · common stock
No tracked investor reported shares of THERAVANCE BIOPHARMA INC (TBPH) for Q2 2026. Joel Greenblatt sold out of its position this quarter.
Holders · Q2 2026
0
New holders
0
Value held
$0
Quarter-end price (est.)
—
Investors holding TBPH · Q2 2026
No tracked investor reported shares this quarter.
Sold out this quarter
| Investor | Prior weight | Prior shares | Prior value | Change |
|---|---|---|---|---|
| Joel Greenblatt | 0.00% | 45,212 | $733.8K | EXIT |
History
| Quarter | Holders | New | Sold out | Value held | Quarter-end price (est.) |
|---|---|---|---|---|---|
| Q2 2026 | 0 | 0 | 1 | $0 | — |
| Q1 2026 | 1 | 0 | 0 | $733.8K | $16.23 |
| Q4 2025 | 1 | 0 | 0 | $424.3K | $18.71 |
| Q3 2024 | 0 | 0 | 1 | $0 | — |
| Q2 2024 | 1 | 0 | 0 | $35.6M | $8.48 |
| Q1 2024 | 1 | 0 | 0 | $59.1M | $8.97 |
| Q4 2023 | 1 | 0 | 0 | $83.4M | $11.24 |
| Q3 2023 | 1 | 0 | 0 | $64M | $8.63 |
| Q2 2023 | 1 | 0 | 0 | $76.8M | $10.35 |
| Q1 2023 | 1 | 0 | 0 | $113M | $10.85 |
| Q4 2022 | 1 | 0 | 0 | $128.1M | $11.22 |
| Q3 2022 | 1 | 0 | 0 | $136.1M | $10.14 |
| Q2 2022 | 1 | 0 | 0 | $121.6M | $9.06 |
| Q1 2022 | 1 | 0 | 0 | $130.4M | $9.56 |
| Q4 2021 | 1 | 0 | 0 | $150.9M | $11.05 |
| Q3 2021 | 1 | 0 | 0 | $101.1M | $7.40 |
| Q2 2021 | 1 | 0 | 0 | $143.9M | $14.52 |
| Q1 2021 | 1 | 0 | 0 | $178.3M | $20.41 |
| Q4 2020 | 1 | 0 | 0 | $155.2M | $17.77 |
| Q3 2020 | 1 | 0 | 0 | $129.1M | $14.78 |
| Q2 2020 | 1 | 0 | 0 | $195.4M | $20.99 |
| Q1 2020 | 1 | 0 | 0 | $215.1M | $23.11 |
| Q4 2019 | 1 | 0 | 0 | $241M | $25.89 |
| Q3 2019 | 1 | 0 | 0 | $181.3M | $19.48 |
| Q2 2019 | 1 | 0 | 0 | $152M | $16.33 |
| Q1 2019 | 1 | 0 | 0 | $211M | $22.67 |
| Q4 2018 | 1 | 0 | 0 | $238.2M | $25.59 |
| Q3 2018 | 1 | 0 | 0 | $304.1M | $32.67 |
| Q2 2018 | 1 | 0 | 0 | $211.1M | $22.68 |
| Q1 2018 | 1 | 0 | 0 | $225.7M | $24.25 |
| Q4 2017 | 1 | 0 | 0 | $259.6M | $27.89 |
| Q3 2017 | 1 | 0 | 0 | $318.7M | $34.24 |
| Q2 2017 | 1 | 0 | 0 | $369.5M | $39.84 |
| Q1 2017 | 1 | 0 | 0 | $341.5M | $36.82 |
| Q4 2016 | 1 | 0 | 0 | $295.7M | $31.88 |
| Q3 2016 | 1 | 0 | 0 | $266.4M | $36.24 |
| Q2 2016 | 1 | 0 | 0 | $166.8M | $22.69 |
| Q1 2016 | 1 | 0 | 0 | $122.2M | $18.80 |
| Q4 2015 | 1 | 0 | 0 | $105.2M | $16.39 |
| Q3 2015 | 1 | 0 | 0 | $70.6M | $10.99 |
| Q2 2015 | 1 | 0 | 0 | $83.6M | $13.02 |
| Q1 2015 | 1 | 0 | 0 | $110.5M | $17.35 |
| Q4 2014 | 1 | 0 | 0 | $90.4M | $14.92 |
| Q3 2014 | 1 | 0 | 0 | $139.7M | $23.05 |
| Q2 2014 | 1 | 1 | 0 | $193.2M | $31.88 |